MSC Efficacy Prediction via Immune Cell Assays
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cell therapies, such as those using mesenchymal stem cells (MSCs), face challenges in predicting individual patient responses to treatment, leading to variability in efficacy and increased costs due to the need for HLA matching.
Innovation Solution
A method for in vitro prediction of treatment efficacy involves assessing the reaction of a patient's immune cells to a drug product, the reaction of the drug product to the patient's immune cells, and the presence of preexisting antibodies against the drug product, using multiple functional and potency assays.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If HLA matching is performed to ensure treatment efficacy, then treatment reliability is improved, but device complexity and cost increase
Solution Approach 1:
The patent performs in vitro prediction assays before treatment to assess patient response likelihood. Multiple functional and potency assays are conducted in advance to evaluate immune cell reactions and antibody presence, allowing treatment selection based on predicted efficacy rather than complex HLA matching
Solution Approach 2:
The patent extracts and evaluates specific key parameters (immune cell reaction, potency, antibody presence) separately through dedicated assays, rather than performing comprehensive HLA matching. This selective extraction of critical factors simplifies the overall process while maintaining predictive accuracy
2Measurement precision
If multiple functional and potency assays are performed to predict treatment efficacy, then measurement precision is improved, but loss of time increases
Solution Approach 1:
The patent divides the efficacy prediction into multiple separate functional and potency assays, each evaluating specific aspects (immune cell reaction, potency, antibody presence). This segmentation allows parallel execution of assays and focused evaluation of critical parameters, improving overall prediction accuracy while enabling efficient time management
Solution Approach 2:
The patent changes the approach from comprehensive HLA typing to measuring specific functional parameters (immune cell reactivity, potency metrics, antibody levels). This parameter transformation enables more direct and accurate efficacy prediction through biologically relevant measurements rather than genetic markers
3Productivity
If off the shelf drug products are used without HLA matching, then productivity and cost are improved, but treatment reliability decreases
Solution Approach 1:
The patent implements a feedback mechanism where in vitro assay results from patient immune cells directly inform treatment decisions. The functional and potency assays provide feedback on predicted patient response, allowing selection of appropriate off-the-shelf products based on actual predicted efficacy rather than HLA compatibility
Solution Approach 2:
The patent introduces in vitro prediction assays as an intermediary between off-the-shelf drug products and patient treatment. These assays mediate the selection process by evaluating patient-specific factors (immune cell reactions, antibody presence) to bridge the gap between standardized products and personalized treatment needs
Data Source
AI summary
The present invention relates to a method of in vitroprediction of the in vivoefficacy in a patient of treatment with a drug product based on an overall assessment of the properties patients own immune cells when exposed to the drug product with and/0 or without stimulation; the drug product when exposed to said patients own immune cells; and any preexisting antibodies against said drug product in said patient.